immuno oncology frontiers world miami


William Loging

Dr William Loging

, Previously at Mount Sinai

Dr. Loging has spent the past 20 years focusing on generating treatments for human disease. Bridging both clinical genomics and pharmaceutical sciences, he have been globally recognized for his work with Maraviroc (Selzentry™) for use in HIV. The results of past his contribution to the approval of Empagliflozin (Jardiance™) were listed within the drug insert. He has published in several leading scientific journals on utilization of novel informatics approaches to Drug Discovery and his 2014 TEDx talk on Cancer Genomics was highly acclaimed.

  • "Great venue to solidify and harmonize on the current challenges facing this sector - in real time. The caliber of the speakers and session contents was premier. “
    Dolores Baksh
    Innovation Leader, GE Healthcare
  • “A great event to learn about the hurdles that are needed to be overcome to get through the clinic.”
    Devin Bridgen
    Scientist, strategic partnerships, SQZ Biotech
  • "It was a great opportunity to share current data and thinking about the development of therapeutics directed at modulating the immune response to cancer."
    Lance Leopold
    Vice President, Head of Oncology Development, Incyte Corporation
  • "Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field."
    Dr James Trager
    Vice President, Research & Product Development, Dendreon
  • “In the rapidly moving Advanced Therapy market, Phacilitate remains one of the premier events.”
    David James
    CEO, Scinogy